EDIT Editas Medicine Inc

Price (delayed)

$10.06

Market cap

$823.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.02

Enterprise value

$735.93M

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a ...

Highlights
EDIT's EPS is up by 37% year-on-year and by 25% since the previous quarter
Editas Medicine's net income has increased by 30% YoY and by 21% QoQ
The debt has contracted by 17% YoY but it has grown by 6% from the previous quarter
Editas Medicine's quick ratio has decreased by 12% QoQ and by 9% YoY
EDIT's equity is down by 3.2% year-on-year and by 3.2% since the previous quarter

Key stats

What are the main financial stats of EDIT
Market
Shares outstanding
81.81M
Market cap
$823.05M
Enterprise value
$735.93M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.35
Price to sales (P/S)
9.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.42
Earnings
Revenue
$78.12M
EBIT
-$170.79M
EBITDA
-$164.72M
Free cash flow
-$136.9M
Per share
EPS
-$2.02
Free cash flow per share
-$1.8
Book value per share
$4.27
Revenue per share
$1.03
TBVPS
$6.57
Balance sheet
Total assets
$499.15M
Total liabilities
$150.06M
Debt
$36.54M
Equity
$349.1M
Working capital
$277.61M
Liquidity
Debt to equity
0.1
Current ratio
5.39
Quick ratio
5.27
Net debt/EBITDA
0.53
Margins
EBITDA margin
-210.8%
Gross margin
100%
Net margin
-196.1%
Operating margin
-216.6%
Efficiency
Return on assets
-30.5%
Return on equity
-43%
Return on invested capital
-50%
Return on capital employed
-39.2%
Return on sales
-218.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EDIT stock price

How has the Editas Medicine stock price performed over time
Intraday
-9.12%
1 week
26.86%
1 month
31.85%
1 year
11.28%
YTD
-0.69%
QTD
-0.69%

Financial performance

How have Editas Medicine's revenue and profit performed over time
Revenue
$78.12M
Gross profit
$78.12M
Operating income
-$169.18M
Net income
-$153.22M
Gross margin
100%
Net margin
-196.1%
The net margin has soared by 82% YoY and by 75% from the previous quarter
EDIT's operating margin has surged by 81% year-on-year and by 74% since the previous quarter
Editas Medicine's net income has increased by 30% YoY and by 21% QoQ
EDIT's operating income is up by 25% year-on-year and by 19% since the previous quarter

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation
P/E
N/A
P/B
2.35
P/S
9.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.42
EDIT's EPS is up by 37% year-on-year and by 25% since the previous quarter
EDIT's P/B is 41% below its 5-year quarterly average of 4.0 but 31% above its last 4 quarters average of 1.8
EDIT's equity is down by 3.2% year-on-year and by 3.2% since the previous quarter
The P/S is 78% less than the 5-year quarterly average of 44.4 and 56% less than the last 4 quarters average of 22.0

Efficiency

How efficient is Editas Medicine business performance
EDIT's return on sales has surged by 81% year-on-year and by 74% since the previous quarter
Editas Medicine's ROA has increased by 22% YoY and by 21% from the previous quarter
The ROE has increased by 21% from the previous quarter and by 15% YoY
EDIT's return on invested capital is up by 20% year-on-year and by 18% since the previous quarter

Dividends

What is EDIT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time
The current ratio has contracted by 12% from the previous quarter and by 9% YoY
Editas Medicine's quick ratio has decreased by 12% QoQ and by 9% YoY
The debt is 90% less than the equity
The debt has contracted by 17% YoY but it has grown by 6% from the previous quarter
The company's debt to equity fell by 17% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.